Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Jianlin Xu Author
Subjects of specialization
Affiliation
Colorectal cancer, Cancer chemotherapy, Prostate biomarker, Endometrial cancer
Biologics Process Development, Global Manufacturing and Supply, Bristol- Myers Squibb Company, Devens, Massachusetts, USA
Biography
Jianlin Xu was working in the Biologics Process Development, Global Manufacturing and Supply, Bristol- Myers Squibb Company, Devens, Massachusetts, USA. He has more than 40 publications. His current research area related to Endometrial cancer
Publications
Review Article Open Access
Screening of Monoclonal Antibodies for Cancer Treatment
Author(s): Peifeng Tang, Shaoyan Liang, Jianlin Xu, Shaoxiong Wang, Lijun Wang and Shijie Liu*
With the rapid development of cancer treatment using monoclonal antibodies (mAbs), the screening process of suitable biologics and indications attracts much attention. A general definition of ‘screening’ in the biopharmaceutical industry includes three aspects: the appropriate biologics for the specific cancers, the appropriate indications for the specific biologics and the promising biologic candidates from the pool at the pre-clinical drug discovery stage. Effective screening strategies in the biopharmaceutical industry are crucial to accelerate the drug commercialization process and select the effective biologics for patients. The current status of commercial mAbs and the global pharmaceutical market was briefly reviewed. The mechanism of comm... view more»
Google Scholars / Researchers Sites
